The gut microbiota plays a pivotal role in immune regulation, supporting innate immune responses, germinal center formation within lymphoid tissues, and the induction of oral tolerance to dietary antigens
Their approach-layering oral, injectable, and combination therapies-shows a strategic understanding that obesity treatment isnt one-size-fits-all
Lillys Zepbound, approved in November 2023 as the Indiana-based drug giants answer to Novo Nordisks Wegovy, showed 21% average weight loss after 72 weeks for its highest dose in its Phase 3 trial, and a mid-stage study of another Lilly experimental medicine, called retatrutide, showed 24% weight loss after just 48 weeks
Continued analysis is underway in this regard [10, 11]
To qualify for tirzepatide for weight loss , individuals typically need to have a body mass index (BMI) of 30 or higher, which is classified as obesity